Holen Sie sich die Stockscreener-App
12.85
10.89%
-1.57
Handel nachbörslich:
12.30
-0.55
-4.28%
Schlusskurs vom Vortag:
$14.42
Offen:
$14.49
24-Stunden-Volumen:
347.20K
Relative Volume:
3.00
Marktkapitalisierung:
$601.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+86.23%
1M Leistung:
+131.95%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$12.15
$15.00
1-Wochen-Bereich:
$6.7327
$15.37
52-Wochen-Spanne:
$3.4341
$15.37
Capsovision Inc Stock (CV) Company Profile
Firmenname
Capsovision Inc
Sektor
Branche
Telefon
(408) 370-4790
Adresse
18805 COX AVENUE SUITE 250, SARATOGA
Vergleichen Sie CV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
12.85 | 675.48M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
125.46 | 214.37B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.58 | 136.01B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.09 | 134.98B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.87 | 127.88B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.08 | 48.88B | 5.88B | 1.34B | 799.60M | 2.3489 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Roth Capital | Buy |
| 2025-07-28 | Eingeleitet | The Benchmark Company | Speculative Buy |
Capsovision Inc Aktie (CV) Neueste Nachrichten
CapsoVision (NASDAQ: CV) Stock Rockets After-Hours: Price Action, Q3 Earnings and 2026 Outlook - ts2.tech
Oxford Industries, Ur-Energy, Oracle And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Is CapsoVision Showing How Far A Single Capsule Can Take A Med-Tech Company? - RTTNews
What Sparked CapsoVision's (CV) 53% Surge In After-Hours Trading? - Benzinga
A look into CapsoVision Inc (CV)’s deeper side - setenews.com
CapsoVision Welcomes David Garcia to its Senior Executive Team - Medical Product Outsourcing
CapsoVision (CV) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CapsoVision reports Q3 EPS (17c) vs ($2.79) last year - MSN
CapsoVision to Participate in the Benchmark 14th Annual Discovery Investor Conference - GlobeNewswire
CapsoVision (NASDAQ: CV) to Host 1:1 Investor Meetings at Benchmark Discovery Conference - Stock Titan
CapsoVision, Inc.Common Stock (NQ: CV - FinancialContent
FY2028 EPS Estimates for CapsoVision Cut by Roth Capital - MarketBeat
CapsoVision (CV) Price Target Increased by 20.00% to 6.12 - Nasdaq
CapsoVision CFO Kevin Lundquist Steps Down - MSN
David Michael Garcia Net Worth (2025) - GuruFocus
Benchmark reiterates Speculative Buy rating on CapsoVision stock at $5 By Investing.com - Investing.com Australia
Benchmark reiterates Speculative Buy rating on CapsoVision stock at $5 - Investing.com
CapsoVision Reports Revenue Growth and Strategic Advances - TipRanks
CapsoVision Q3 2025 Earnings Call Transcript - MarketBeat
CapsoVision, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
CapsoVision, Inc. (CV) Q3 FY2025 earnings call transcript - Yahoo Finance
[8-K] CapsoVision, Inc Reports Material Event | CV SEC FilingForm 8-K - Stock Titan
CapsoVision Reports Third Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Inc (CV) Q3 2025 Earnings Report Preview: What to Ex - GuruFocus
CapsoVision Inc (CV) Q3 2025 Earnings Report Preview: What to Expect - Yahoo Finance
CapsoVision CFO Lundquist steps down - MSN
CapsoVision Seeks FDA Breakthrough Status for CapsoCam - MSN
CapsoVision seeks FDA breakthrough status for pancreatic cancer tool By Investing.com - Investing.com Nigeria
CapsoVision Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening Capsule - The Manila Times
CapsoVision seeks FDA breakthrough status for pancreatic cancer tool - Investing.com
Q3 Earnings Forecast for CapsoVision Issued By Roth Capital - MarketBeat
CapsoVision (NASDAQ:CV) and Bioventus (NASDAQ:BVS) Financial Contrast - Defense World
Roth Capital Upgrades CapsoVision (NASDAQ:CV) to Strong-Buy - Defense World
United States Smart Pills Market to hit US$ 619.10 Million by 2033 - openPR.com
CapsoVision appoints David Garcia as SVP of finance By Investing.com - Investing.com Australia
[Form 3] CapsoVision, Inc Initial Statement of Beneficial Ownership - Stock Titan
[Form 4] CapsoVision, Inc Insider Trading Activity - Stock Titan
Capsovision, Inc. Appoints David Garcia as Senior Vice President of Finance and Principal Accounting Officer, Effective November 3, 2025 - MarketScreener
CapsoVision Appoints David Garcia as Finance VP - TipRanks
CapsoVision appoints David Garcia as SVP of finance - Investing.com
CapsoVision Appoints David Garcia as Senior Vice President of Finance - The Manila Times
CapsoVision Appoints New Principal Financial Officer - TradingView
CapsoVision, Inc. Appoints David Garcia as Principal Financial Officer, Effective from November 3, 2025 - MarketScreener
CapsoVision (NASDAQ: CV) names David Garcia SVP of Finance; ex-Matterport FP&A VP - Stock Titan
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025 - The Manila Times
CapsoVision (NASDAQ:CV) & Bioventus (NASDAQ:BVS) Critical Review - Defense World
Weiss Ratings Reaffirms "Sell (E-)" Rating for CapsoVision (NASDAQ:CV) - MarketBeat
Finanzdaten der Capsovision Inc-Aktie (CV)
Es liegen keine Finanzdaten für Capsovision Inc (CV) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.52%
0.28%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):